Our pipeline starts with strong science; aimed at translating immunology breakthroughs into differentiated medicines.
argenx engineers first-in-class therapies for rare diseases – where underserved patients need breakthroughs and the healthcare community needs options.
Our franchise-focused approach to development has created a pipeline that is as broad as it is deep, allowing us to advance select opportunities ourselves while partnering others.
- Primary ITP is a rare, often chronic disorder where IgG antibodies cause reduced numbers of platelets leading to an increased risk of bleeding and bruising
- IV efgartigimod and SC efgartigimod
- CIDP is a rare, chronic disorder where damage to peripheral nerves, which may be caused by antibodies, results in progressive weakness and a loss of feeling in the arms and legs
- SC efgartigimod
- ARGX-117 is designed to block complement activity with potential to reduce tissue inflammation and the adaptive immune response
- IV ARGX-117 and SC ARGX-117 (enabled with Halozyme's ENHANZE® drug delivery technology)
IV + SC
IV + SC
AML is a type of cancer in which the bone marrow makes abnormal myeloblasts that build up in the bone marrow and blood, resulting in low or no production of normal blood cells (platelets, red blood cells, white blood cells)
Preclinical pipeline candidates
argenx has several assets that emerged from the Immunology Innovation Program that have been out-licensed to a partner for further development.
LP0145 (ARGX-112) was designed as a SIMPLE Antibody® to block receptor, IL22R. LEO Pharma is evaluating the antibody for atopic dermatitis.
AgomAb Therapeutics, a privately held, venture-backed company (www.agomab.com) exclusively licensed the SIMPLE Antibody® technology to generate a set of HGF-mimetic agonists directed at the MET receptor. The lead antibody, AGMB-101 (previously referred to as ARGX-114), has the potential to regenerate damaged tissue in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
ARGX-115, now known as ABBV-151, was designed as a SIMPLE Antibody® inhibitor of GARP-TGF-β1 and is being investigated by AbbVie for the treatment of cancer. ARGX-115 is designed to block GARP and to reactive the immune system against tumors.
STT-5058 (ARGX-116) was designed as a SIMPLE Antibody® inhibitor of ApoC3. STT-5058 is a sweeping antibody with recycling properties that are pH-dependent and enable clearing multiple apoC3-containing lipoproteins. Staten is evaluating the antibody for its potential in dyslipidemia management in collaboration with Novo Nordisk.